Fig. 5From: Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncologyNormalized in vitro cellular processing showing % of total cell associated activity (solid line) and fraction of activity internalized (dotted line) for a [111In]In-AU-SAR-M1, b [111In]In-AU-SAR-M2 and c [111In]In-AU-SAR-M3Back to article page